| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | Crinetics Pharmaceuticals, I | Jul 30, 2026 | |
| Buy | Crinetics Pharmaceuticals, I | Mar 3, 2026 | |
| Buy | Crinetics Pharmaceuticals, I | Apr 17, 2025 | |
| Sell | Crinetics Pharmaceuticals, I | Mar 19, 2025 | |
| Buy | Crinetics Pharmaceuticals, I | Jan 29, 2025 | |
| Buy | Crinetics Pharmaceuticals, I | Sep 25, 2024 | |
| Buy | CRINETICS PHARMACEUTICALS IN | Aug 23, 2021 |
This page tracks congressional stock trading activity in Crinetics Pharmaceuticals, Inc. (CRNX) in the Healthcare sector. Disclosed Capitol has indexed 7 disclosed congressional trades involving CRNX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of September 2026 — Disclosed Capitol has tracked 7 disclosed congressional trades in Crinetics Pharmaceuticals, Inc. (CRNX) — 1:1 buy-heavy ratio — led by Gilbert Cisneros (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jul 30, 2026 | Gilbert Cisneros | D | Sell | $15,001 - $50,000 |
| Mar 3, 2026 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Apr 17, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Mar 19, 2025 | Josh Gottheimer | D | Sale | $1,001 - $15,000 |
| Jan 29, 2025 | Gilbert Cisneros | D | Buy | $1,001 - $15,000 |
| Sep 25, 2024 | Josh Gottheimer | D | Buy | $1,001 - $15,000 |
| Aug 23, 2021 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
Across the 7 disclosed congressional trades in Crinetics Pharmaceuticals, Inc. (CRNX), members of Congress have reported 1 buy and 1 sell. The average 30-day alpha vs. the S&P 500 is 0.39%.
For fiscal year 2025, Crinetics Pharmaceuticals, Inc. reported revenue of $7.7M and net income of -$465.3M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $25.1M, net income -$120.9M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.